These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34730979)

  • 1. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy.
    He L; Wang L; Wang Z; Li T; Chen H; Zhang Y; Hu Z; Dimitrov DS; Du J; Liao X
    J Med Chem; 2021 Nov; 64(21):15716-15726. PubMed ID: 34730979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
    Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
    Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation.
    Xiao D; Luo L; Li J; Wang Z; Liu L; Xie F; Feng J; Zhou X
    Bioorg Chem; 2021 Nov; 116():105366. PubMed ID: 34560561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
    Wu Y; Chen W; Xu ZP; Gu W
    Front Immunol; 2019; 10():2022. PubMed ID: 31507611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates.
    Fang S; Brems BM; Olawode EO; Miller JT; Brooks TA; Tumey LN
    Mol Pharm; 2022 Sep; 19(9):3228-3241. PubMed ID: 35904247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.
    Taki S; Matsuoka K; Nishinaga Y; Takahashi K; Yasui H; Koike C; Shimizu M; Sato M; Sato K
    J Immunother Cancer; 2021 Oct; 9(11):. PubMed ID: 34725216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
    Zhai W; Zhou X; Du J; Gao Y
    Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
    Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.